Interatrial block, P terminal force or fragmented QRS do not predict new-onset atrial fibrillation in patients with severe chronic kidney disease

Tapio Hellman 1*, Markus Hakamäki 1, Roosa Lankinen 1, Niina Koivuviita 1, Jussi Pärkkä 2, Petri Kallio 2,3, Tuomas Kiviniemi 4, K. E. Juhani Airaksinen 4, Mikko J. Järvisalo 5,6 and Kaj Metsärinne 1

Abstract

Background: The prevalence of left atrial enlargement (LAE) and fragmented QRS (fQRS) diagnosed using ECG criteria in patients with severe chronic kidney disease (CKD) is unknown. Furthermore, there is limited data on predicting new-onset atrial fibrillation (AF) with LAE or fQRS in this patient group.

Methods: We enrolled 165 consecutive non-dialysis patients with CKD stage 4–5 without prior AF diagnosis between 2013 and 2017 in a prospective follow-up cohort study. LAE was defined as total P-wave duration ≥ 120 ms in lead II ± > 1 biphasic P-waves in leads II, III or aVF; or duration of terminal negative portion of P-wave > 40 ms or depth of terminal negative portion of P-wave > 1 mm in lead V1 from a baseline ECG, respectively. fQRS was defined as the presence of a notched R or S wave or the presence of ≥ 1 additional R waves (R') or, in the presence of a wide QRS complex (> 120 ms), > 2 notches in R or S waves in two contiguous leads corresponding to a myocardial region, respectively.

Results: Mean age of the patients was 59 (SD 14) years, 56/165 (33.9%) were female and the mean estimated glomerular filtration rate was 12.8 ml/min/1.73m². Altogether 29/165 (17.6%) patients were observed with new-onset AF within median follow-up of 3 [IQR 3, range 2–6] years. At baseline, 137/165 (83.0%) and 144/165 (87.3%) patients were observed with LAE and fQRS, respectively. Furthermore, LAE and fQRS co-existed in 121/165 (73.3%) patients. Neither findings were associated with the risk of new-onset AF within follow-up.

Conclusion: The prevalence of LAE and fQRS at baseline in this study on CKD stage 4–5 patients not on dialysis was very high. However, LAE or fQRS failed to predict occurrence of new-onset AF in these patients.

Keywords: Atrial fibrillation, Chronic kidney disease, Left atrial enlargement, Fragmented QRS, Incidence

Background

Patients with chronic kidney disease (CKD) have a high prevalence and incidence of atrial fibrillation (AF), which further increases the already high risk for cardiovascular events as well as accelerated CKD progression in affected patients [1–3]. Several clinical risk factors for AF have been identified in CKD patients [4, 5]. While interatrial block (IAB), P-wave terminal force (PTF), and fragmented QRS (fQRS) have been linked to the incidence of new-onset AF in selected patient groups in previous studies, data on predicting AF with ECG biomarkers in patients with severe CKD is scarce [6–9].

Thus, we sought to investigate the prevalence of ECG characteristics reflecting the presence of left atrial
enlargement (LAE) and fQRS as well as their predictive performance on new-onset AF in patients with CKD stage 4–5 in a prospective follow-up study.

Methods
The Chronic Arterial Disease, quality of life and mortality in chronic KIDney injury (CADKID)-study (http://www.ClinicalTrials.gov NCT04227326) is a prospective follow-up cohort study assessing cardiovascular disease, quality of life, and mortality in patients with CKD stage 4–5. This paper is a prespecified report from the CADK ID study.

The inclusion criteria for the CADKID-study were CKD stage 4–5 defined as estimated glomerular filtration rate (eGFR) < 30 ml/min per 1.73 m² calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, age over 18 years and residency in the catchment area of the hospital district of South West Finland.

Altogether 210 consecutive patients referred to the predialysis outpatient clinic of the Kidney Center of Turku University Hospital in 2013–2017 were recruited for the main CADKID study. As the present report focuses on ECG characteristics in patients with severe CKD and AF prediction, 41 patients with prior AF diagnosis, 3 patients with new-onset AF observed in the baseline ECG and 1 patient with ventricular pacemaker rhythm in the baseline ECG were excluded. Thus, the study cohort comprised 165 patients.

Relevant medical history and medications at baseline as well as all follow-up data were manually collected from the patient registry by the researchers. The baseline laboratory tests and a 12-lead surface electrocardiogram (ECG) were gathered by the certified laboratory services of Turku University Hospital (TYKSLAB). The patients were regularly at least every three months followed-up and interviewed for AF related symptoms in the research hospital. ECGs or 24 h ECG recordings were collected from all symptomatic patients while regular follow-up ECGs were not recorded.

The ECG recording settings were set at the paper speed of 50 mm per second and the standardized voltage ratio of 1 mm per 1 mV. The total P-wave duration was assessed in the lead II, the duration and depth of the terminal negative portion of P-wave in lead V1 and the number of biphasic P-waves in the inferior leads II, III and aVF, respectively. All ECGs were manually assessed in pdf format and digital magnification up to 400% without diminishing image quality by the researchers.

The presence of LAE was defined according to following ECG criteria: total P-wave duration ≥120 ms measured in lead II (definition of first degree IAB) or P-wave duration ≥120 ms measured in lead II and more than one biphasic P-waves in leads II, III or aVF (definition of third degree IAB); or duration of terminal negative portion of P-wave > 40 ms measured in lead V1, or depth of terminal negative portion of P-wave > 1 mm measured in lead V1 or PTF > 0.04 mm·s (defined as the product of the duration and depth of the terminal negative portion of P-wave in lead V1) (Fig. 1). The presence of fQRS was defined according to ECG criteria: notching in the nadir of R or S wave or the presence of one or more additional R waves (R′) or, in the presence of a wide QRS complex (> 120 ms), more than two notches in R or S waves in at least two contiguous leads corresponding to a myocardial region with leads V1-V4, leads V5-V6 and I and aVL, and leads II-III and aVF denoting anterior, lateral and inferior myocardial regions, respectively [10] (Fig. 1).

The primary end-point of the study was the occurrence of new-onset AF confirmed by ECG or pacemaker log.

Statistics
Normally distributed continuous covariates were reported as mean ± standard deviation (SD), skewed continuous variables as median [inter-quartile range (IQR)] and categorical covariates with absolute and relative (percentage) frequencies. Kolmogorov-Smirnov and Shapiro-Wilk tests were used to assess normality in continuous covariates. Continuous covariates and categorical covariates were compared using the unpaired t-test or Mann-Whitney test and Pearson × 2 or Fisher’s exact test, respectively. Baseline covariates correlating at p < 0.10 significance level with the dependent covariate in the univariate analysis were entered in the multivariate logistic regression analysis. All tests were two-sided and significance was set at p = 0.05. IBM SPSS Statistics software version 26.0 was used to perform all analyses.

Results
Mean age of the study patients was 59 (SD 14) years and 56/165 (33.9%) were female. Altogether, 160/165 (97.0%) patients had a history of hypertension, 24/165 (14.5%) had heart failure, 71/165 (43.0%) had diabetes, and 17/165 (10.3%) had coronary artery disease (CAD), respectively. The mean eGFR was 12.8 ml/min/1.73m². Overall 29/165 (17.6%) patients were diagnosed with new-onset AF during a median follow-up of 3 [IQR 3, range 2–6] years. The median time to occurrence of new-onset AF was 18 [IQR 26, range 2–66] months. Out of the 29 patients with new-onset AF, 25 (86.2%), 2 (6.9%) and 2 (6.9%) patients were diagnosed with paroxysmal AF,
long-standing persistent AF (defined as AF episode lasting up to one year) and chronic AF, respectively.

The ECG characteristics of patients according to the occurrence of new-onset AF are depicted in Table 1. Overall, 137/165 (83.0%) patients had LAE at baseline. Furthermore, IAB and PTF were present in 92/165 (55.8%) and 44/165 (26.7%) patients, respectively (Fig. 2). The patients with LAE were older and had longer QRS duration and higher N-terminal pro b-type natriuretic peptide (NT-ProBNP) in the univariate analysis. In the multivariate logistic regression analysis a QRS duration ≥100 ms (OR 4.20, CI95% 1.36–12.95, \( p = 0.01 \)) independently predicted LAE in the baseline ECG. However, the presence of LAE was not associated with the incidence of new-onset AF.

Altogether 144/165 (87.3%) patients had fQRS in at least two contiguous leads in the baseline ECG. fQRS was observed in 55/165 (33.3%), 73/165 (44.2%), and 125/165 (75.8%) for anterior, lateral and inferior leads, respectively (Fig. 2). fQRS was present in multiple myocardial regions in 89/165 (53.9%) patients as well as in six of the nine patients with wide (> 120 ms) QRS complex. Younger age and absence of prior CAD diagnosis were associated with fQRS in the univariate analysis but no significant associations with fQRS were observed in the multivariate model. Although, the presence of fQRS in all myocardial regions in the baseline ECG was associated with a lower rate of new-onset AF in the univariate analysis (Table 1), overall, fQRS was not associated with the occurrence of new-onset AF. LAE and fQRS coexisted in 121/165 (73.3%) patients (Fig. 2).

The results considering AF prediction remained unchanged when the analyses were applied to patients who developed new-onset AF within one year or three years of follow-up or to those who developed new-onset long-standing persistent or chronic AF (data not shown).

**Discussion**

This is the first study to assess the prevalence of both LAE and fQRS and their association with AF incidence in a large cohort of non-dialysis patients with CKD stage 4–5. The prevalence of, both, LAE and fQRS in the
baseline ECG was remarkably high in this study. Furthermore, three quarters of patients were observed with both ECG patterns— a perception not demonstrated before in CKD patients. However, neither LAE nor fQRS were associated with the incidence of new-onset AF in this study.

The prevalence of IAB and PTF was high in our patients with severe CKD not on dialysis and the rate of

| Table 1 Electrocardiogram characteristics of patients according to incidence of new-onset AF during follow-up |
|---------------------------------------------------------------|
| **ECG**                                                      |
| PR-interval<sup>a</sup>                                      |
| mean (median) ms                                             |
| No AF (N = 136)                                              |
| 176 (168)                                                    |
| Incident AF (N = 29)                                         |
| 180 (168)                                                    |
| p                                                             |
| 0.48                                                         |
| P-wave duration<sup>a</sup>                                  |
| mean (median) ms                                             |
| No AF (N = 136)                                              |
| 117 (120)                                                    |
| Incident AF (N = 29)                                         |
| 118 (120)                                                    |
| p                                                             |
| 0.79                                                         |
| Biphasic P-waves (> 1)<sup>b</sup>                           |
| Terminal P negativity depth                                  |
| mean (median) mV<sup>c</sup>                                 |
| No AF (N = 136)                                              |
| 0.5 (0.5)                                                    |
| Incident AF (N = 29)                                         |
| 0.6 (0.5)                                                    |
| p                                                             |
| 0.39                                                         |
| Terminal P negativity duration                               |
| mean (median) mm<sup>c</sup>                                 |
| No AF (N = 136)                                              |
| 56 (50)                                                      |
| Incident AF (N = 29)                                         |
| 53 (60)                                                      |
| p                                                             |
| 0.65                                                         |
| IAB<sup>d</sup>                                              |
| No AF (N = 136)                                              |
| 75 (55.1)                                                    |
| Incident AF (N = 29)                                         |
| 17 (58.6)                                                    |
| p                                                             |
| 0.84                                                         |
| PTF > 0.04 mm*s<sup>e</sup>                                  |
| No AF (N = 136)                                              |
| 33 (24.3)                                                    |
| Incident AF (N = 29)                                         |
| 11 (37.9)                                                    |
| p                                                             |
| 0.17                                                         |
| LAE<sup>f</sup>                                              |
| No AF (N = 136)                                              |
| 113 (83.1)                                                   |
| Incident AF (N = 29)                                         |
| 24 (82.8)                                                    |
| p                                                             |
| 1.0                                                          |
| QRS duration mean (median) ms                                |
| No AF (N = 136)                                              |
| 98 (95)                                                      |
| Incident AF (N = 29)                                         |
| 97 (96)                                                      |
| p                                                             |
| 0.94                                                         |
| QTc duration mean (median) ms                                |
| No AF (N = 136)                                              |
| 442 (439)                                                    |
| Incident AF (N = 29)                                         |
| 426 (449)                                                    |
| p                                                             |
| 0.44                                                         |
| QRS axis mean (median) degrees                               |
| No AF (N = 136)                                              |
| 25 (25)                                                      |
| Incident AF (N = 29)                                         |
| 15 (15)                                                      |
| p                                                             |
| 0.15                                                         |
| fQRS<sup>g</sup>                                             |
| No AF (N = 136)                                              |
| 121 (89.0)                                                   |
| Incident AF (N = 29)                                         |
| 23 (79.3)                                                    |
| p                                                             |
| 0.22                                                         |
| fQRS positive leads mean (median)                            |
| No AF (N = 136)                                              |
| 5 (5)                                                        |
| Incident AF (N = 29)                                         |
| 4 (4)                                                        |
| p                                                             |
| 0.07                                                         |
| fQRS positive in anterior leads alone<sup>h</sup>             |
| No AF (N = 136)                                              |
| 5 (3.7)                                                      |
| Incident AF (N = 29)                                         |
| 2 (6.9)                                                      |
| p                                                             |
| 0.61                                                         |
| fQRS positive in lateral leads alone<sup>i</sup>              |
| No AF (N = 136)                                              |
| 9 (6.6)                                                      |
| Incident AF (N = 29)                                         |
| 0 (0)                                                        |
| p                                                             |
| 0.36                                                         |
| fQRS positive in inferior leads alone<sup>j</sup>             |
| No AF (N = 136)                                              |
| 31 (22.8)                                                    |
| Incident AF (N = 29)                                         |
| 8 (27.6)                                                     |
| p                                                             |
| 0.63                                                         |
| fQRS positive in ant + lat leads                             |
| No AF (N = 136)                                              |
| 3 (2.2)                                                      |
| Incident AF (N = 29)                                         |
| 0 (0)                                                        |
| p                                                             |
| 1.0                                                          |
| fQRS positive in ant + inf leads                             |
| No AF (N = 136)                                              |
| 20 (14.7)                                                    |
| Incident AF (N = 29)                                         |
| 5 (17.2)                                                     |
| p                                                             |
| 0.78                                                         |
| fQRS positive in lat + inf leads                             |
| No AF (N = 136)                                              |
| 33 (24.3)                                                    |
| Incident AF (N = 29)                                         |
| 8 (27.6)                                                     |
| p                                                             |
| 0.81                                                         |
| fQRS positive in ant + lat + inf leads                       |
| No AF (N = 136)                                              |
| 20 (14.7)                                                    |
| Incident AF (N = 29)                                         |
| 0 (0)                                                        |
| p                                                             |
| 0.03                                                         |
| Echocardiography                                            |
| LA diameter mean (median) mm<sup>*</sup>                     |
| No AF (N = 136)                                              |
| 40 (39)                                                      |
| Incident AF (N = 29)                                         |
| 44 (42)                                                      |
| p                                                             |
| 0.01                                                         |
| EF mean (median) %                                           |
| No AF (N = 136)                                              |
| 65 (65)                                                      |
| Incident AF (N = 29)                                         |
| 66 (66)                                                      |
| p                                                             |
| 0.22                                                         |
| Laboratory tests                                            |
| NT-ProBNP median (IQR) ng/l                                  |
| No AF (N = 136)                                              |
| 808 (1632)                                                   |
| Incident AF (N = 29)                                         |
| 1390 (5064)                                                  |
| p                                                             |
| 0.10                                                         |
| Clinical characteristics                                     |
| CHA2DS2-VASc-score median (IQR)                              |
| No AF (N = 136)                                              |
| 2 (2)                                                        |
| Incident AF (N = 29)                                         |
| 3 (3)                                                        |
| p                                                             |
| 0.03                                                         |

<sup>a</sup> measured in lead II; <sup>b</sup> measured in leads II, III and aVF; <sup>c</sup> measured in lead V1; <sup>d</sup> defined according to ECG-criteria (total P-wave duration ≥120 ms in lead II ± more than one biphasic P-waves in leads II, III or aVF); <sup>e</sup> defined according to ECG-criteria (the product of the duration (in seconds) and depth (in millimeters) of the terminal negative portion of P-wave in lead V1); <sup>f</sup> defined according to ECG-criteria (total P-wave duration ≥120 ms in lead II ± more than one biphasic P-waves in leads II, III or aVF; or duration of terminal negative portion of P-wave in lead V1 > 40 ms or depth of terminal negative portion of P-wave in lead V1 > 1 mm); <sup>g</sup> defined according to ECG-criteria (presence of a notched R or S wave or the presence of one or more additional R waves (R) or, in the presence of a wide QRS complex (> 120 ms), more than two notches in R or S waves in two contiguous leads corresponding to a major coronary artery, respectively); <sup>h</sup> measured in leads V1-V4; <sup>i</sup> measured in leads V5-V6 and I and aVL; <sup>j</sup> measured in leads II-III and aVF.

Values in parentheses are % unless stated otherwise. ECG = electrocardiogram; IAB = interatrial block; PTF = P terminal force; LAE = left atrial enlargement; fQRS = fragmented QRS; LA = left atrium; EF = ejection fraction; NT-ProBNP = N-terminal pro b-type natriuretic peptide; IQR = inter-quartile range; CHA2DS2-VASc = congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, prior stroke, transient ischemic attack or thromboembolism (doubled), vascular disease, age 65 to 74 years and sex category (female, unless < 65 years and no other risk factors).
both patterns was comparable to previous studies in hemodialysis patients [11, 12]. However, we found no connection between LAE and new-onset AF. The high prevalence of LAE in this study population probably better represents the gross overall cardiovascular disease burden in patients with CKD stage 4–5 than AF risk alone. In fact, both IAB and PTF have been associated with hypertension, CAD and heart failure which were highly prevalent conditions in our study cohort [13–15]. Both IAB and PTF have been described to reflect the presence of LAE and to predict the incidence of new-onset AF in various populations [6, 12, 16–18] but not in CKD patients.

Almost nine patients out of ten were observed with fQRS in our cohort – the highest prevalence reported to date. In previous studies on patients with established structural heart disease or AF, the prevalence of fQRS has ranged between 30 and 50% and the rates have been similar among patients with CKD stage 3–5 [8, 9, 19–21]. As with LAE, the high fQRS rate may partly be explained by the high rate of cardiovascular comorbidities in our study population since fQRS has been associated with diabetes, CAD and, vascular calcification in prior reports [8, 18, 22]. In recent studies, fQRS has been linked to the incidence of new-onset AF in patients with established heart disease, as well as to increased AF recurrence after cardioversion or catheter ablation [8, 9, 19, 23, 24]. It is unclear why no association between AF and fQRS was observed among patients with severe CKD in this study.

There is an unmet need for ECG markers of AF risk due to the high prevalence and often asymptomatic nature of AF among CKD patients. Moreover, incident stroke is often the first symptom of AF [25]. It is, therefore, disappointing that the ECG analysis in our study provided no predictors for AF in CKD patients. The recent advances in technology have brought forth new methods for detecting AF and accordingly, smart device applications have received plentiful attention [26]. Subsequently, older ECG based screening methods have also been newly approached. Recently a sophisticated artificial intelligence algorithm effectively predicted the incidence of AF from standard 12-lead ECGs at sinus rhythm [27]. While the novel approach fared well in a large non-CKD patient cohort, the performance of the algorithm is yet to be tested in CKD patients – especially in advanced CKD.

Patients with severe CKD, in addition to heavy cardiovascular disease burden, are at risk for vascular and tissue calcification [28] and while extensive vascular calcification may greatly increase the prevalence of LAE and fQRS, it may also “drown out” the predictive effect of these ECG biomarkers for AF. Furthermore, uremic toxins and dialysis may have precipitating effects for AF overshadowing ECG markers. Overall, non-dialysis patients with severe CKD appear to possess substantial
substrate for AF, demonstrated by the annual AF incidence of 6% in our study, due to the high rate of co-existing conditions affecting the atria and ventricles assessed by LAE and fQRS. Furthermore, this clustering of risk factors may partly explain the strikingly high prevalence of the co-existence of LAE and fQRS in these patients. While these nonspecific ECG biomarkers possibly reflect high cardiovascular risk burden in CKD patients, they do not appear to predict AF in this population. While further research on ECG biomarkers in this setting is needed, other methods based on clinical risk assessment, biochemistry or echocardiography are likely to perform better in prediction of AF among these highly morbid patients – a matter to be addressed in future reports of the CADKID study.

Limitations
This study has all the limitations of an observational study. The patient cohort was relatively small. However, all the study patients were extensively and consistently studied by the same trained researchers and quality of the data was high. While patients with severe CKD are at increased risk for electrolyte and fluid imbalance – known arrhythmogenic risk factors, conditions such as hyperkalemia or hypervolemia may have caused bias in the study. As AF is often asymptomatic, some self-limited new-onset AF episodes may have been missed. Nevertheless, all the study patients resident in the catchment area, were frequently and regularly, due to CKD severity, in contact with the Kidney Center and all symptomatic AF episodes are consistently recorded in the electronic archives of the research hospital. Despite these limitations, we believe that these data can benefit clinical practice and guide future research.

Conclusions
Our study demonstrated a high prevalence of LAE and fQRS in patients with CKD stage 4–5. Our findings suggest that LAE or fQRS do not predict new-onset AF in these patients.

Abbreviations
CKD: Chronic kidney disease; AF: Atrial fibrillation; IAB: Interalatrial block; PTF: P-wave terminal force; fQRS: Fragmented QRS; ECG: Electrocardiogram; LAE: Left atrial enlargement; CADKID-study: The chronic arterial disease epidemiology collaboration formula; TYKSLAB: The certified laboratory services of Turku University hospital; SD: Standard deviation; IQR: Interquartile range; CAD: Coronary artery disease; NT-ProBNP: N-terminal pro b-type natriuretic peptide; OR: Odds ratio; CI: Confidence interval

Acknowledgements
Not Applicable.

Authors’ contributions
TH, MH, RL, NK, JP, PK, MJ, KM designed the study and were responsible for the data collection. TH performed the statistical analysis. TH drafted the manuscript. TH, MH, NK, TK, KEJA, MJ and KM revised the manuscript. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. The authors read and approved the final manuscript.

Funding
This work was supported by the Finska Läkaresällskapet and the Perklén Foundation, Helsinki, Finland; the Aarne Koskelo Foundation; the expert responsibility area (ERVA) of the Turku University Hospital (TYKS); and the TYKS foundation. The grants were used to collect and analyze the data. The funding bodies were not involved with the design of the study or interpretation of the data.

Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study received approval of the Medical Ethics Committee of the Hospital District of Southwest Finland and the ethics committee of the National Institute for Health and Welfare. The study adheres to the Declaration of Helsinki. Each patient provided written informed consent for the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Kidney Center, Turku University Hospital and University of Turku, Hämeentie 11, PO Box 52, 20521 Turku, Finland. 2Department of Clinical Physiology, Turku University Hospital and University of Turku, Hämeentie 11, PO Box 52, 20521 Turku, Finland. 3Paavo Nurmi Centre & Unit for Health and Physical Activity, University of Turku, Kinnamyllynkatu 10, 20520 Turku, Finland. 4Heart Center, Turku University Hospital and University of Turku, Hämeentie 11, PO Box 52, 20521 Turku, Finland. 5Department of Anaesthesiology and Intensive Care, Turku University Hospital and University of Turku, Hämeentie 11, PO Box 52, 20521 Turku, Finland.

Received: 1 March 2020 Accepted: 30 September 2020
Published online: 07 October 2020

References
1. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, et al. Chronic kidney disease and prevalent atrial fibrillation: the chronic renal insufficiency cohort (CRC). Am Heart J. 2010;159:102–7. https://doi.org/10.1016/j.ahj.2010.03.027.
2. Carrero JJ, Trevisan M, Sood MM, Bárány P, Xu H, Evans M, et al. Incident atrial fibrillation and the risk of stroke in adults with chronic kidney disease: the Stockholm CREATinine measurements (SCREAM) project. Clin J Am Soc Nephrol. 2018;13:1314–20. https://doi.org/10.2215/CJN.04060318.
3. Hsu HH, Kor CT, Hsieh YP, Chiu PF. Effects of Prevalent and Incident Atrial Fibrillation on Renal Outcome, Cardiovascular Events, and Mortality in Patients with Chronic Kidney Disease. J Clin Med. 2019;8. https://doi.org/10.3390/jcm8091378.
4. Shen CH, Zheng CM, Kiu KT, et al. Increased risk of atrial fibrillation in end-stage renal disease patients on dialysis: A nationwide, population-based study in Taiwan. Medicine (Baltimore). 2016;95:e3933. https://doi.org/10.1097/MD.0000000000003933.
5. Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis. 2008;51:255–62. https://doi.org/10.1053/j.ajkd.2007.10.034.
6. Nielsen JB, Küh J, Pietersen A, Graff C, Lind B, Stuik J, et al. P- wave duration and the risk of atrial fibrillation: results from the Copenhagen ECG study. Heart Rhythm. 2015;12:1887–95. https://doi.org/10.1016/j.hrthm.2015.04.026.
7. Goda T, Sugiyama Y, Ohara N, Ikegami T, Watanabe K, Kobayashi J, et al. P-wave terminal force in Lead V1 predicts paroxysmal atrial fibrillation in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2017;26:1912–5. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.06.031.

8. Temiz A, Gazi E, Gungör Ö, Altun B, Barutcu A, Bekler A, et al. Fragmented QRS and prediction of paroxysmal atrial fibrillation episodes. Pak J Med Sci. 2014;30:862–7.

9. Yesin M, Kalçı A, Çağdaş M, Karabğ R, Yençoğullari U, Gungör MO, et al. Fragmented QRS may predict new onset atrial fibrillation in patients with ST-segment elevation myocardial infarction. J Electrocardiol. 2018;51:27–32. https://doi.org/10.1016/j.jelectrocard.2017.08.014.

10. Jain R, Singh R, Yamini S, Das MK. Fragmented ECG as a risk marker in cardiovascular diseases.Curr Cardiol Rev. 2014;10:277–86. https://doi.org/10.2174/1573403X1066614014103451.

11. Bilen Y, Cankaya E, Simşek Z, Koza Y, İpek E, Karakelleoglu S, et al. Relationship between left atrial functions, P-terminal force and interatrial block in chronic haemodialysis patients. Eur Rev Med Pharmacol Sci. 2015; 19:676–71.

12. Jaroszyński A, Jaroszyńska A, Dobrowski W, Zaborowska T, Stepulak A, Ilbecki M, et al. Factors influencing P terminal force in lead V1 of the ECG in hemodialysis patients. Arch Med Sci. 2018;14:257–64. https://doi.org/10.5114/aoms.2017.65926.

13. Eranti A, Aro AL, Kerola T, Anttonen O, Rissanen HA, Tikkanen JT, et al. Prevalence and prognostic significance of abnormal P terminal force in lead V1 of the ECG in the general population. Circ Anhythm Electrophysiol. 2014;7:1116–21. https://doi.org/10.1161/CIRCEP.114.001557.

14. Tereshchenko LG, Shah AJ, Li Y, Solomon EZ. Electrocardiographic deep terminal negativity of the P wave in V1 and risk of mortality: the National Health and nutrition examination survey III. J Cardiovasc Electrophysiol. 2014;25:1242–8. https://doi.org/10.1111/jce.12453.

15. Skov MW, Ghouse J, Kühl JT, Platonov KG, Graff C, Fuchs A, et al. Risk Prediction of Atrial Fibrillation Based on Electrocardiographic Interal Block. J Am Heart Assoc. 2018;7. https://doi.org/10.1161/JAHA.117.008247.

16. Lacabaza-Almeida J, Izquierdo-Gómez MM, Belloso-Belkasem C, Barrio-Martínez P, García-Niebla J, Elías A, et al. Interal block and atrial remodeling assessed using speckle tracking echocardiography. BMC Cardiovasc Disord. 2018;18:38. https://doi.org/10.1186/s12872-018-0776-6.

17. Hazen MS, Vanwick TH, Underwood DA. Diagnostic accuracy of the resting electrocardiogram in detection and estimation of left atrial enlargement: an echocardiographic correlation in 551 patients. Am Heart J. 1991;122:823–71.

18. Magnani JW, Zhu L, Lopez F, Pencina MJ, Agarwal SK, Soliman EZ, et al. P-wave indices and atrial fibrillation: cross-cohort assessments from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2015;169:53–61.e1. https://doi.org/10.1016/j.ahj.2014.10.009.

19. Canpolat U, Mohanty S, Trivedi C, Chen Q, Ayhan H, Gianni C, et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet. 2019;394:861–7. https://doi.org/10.1016/S0140-6736(19)31721-0.

20. Blacher J, Guerin AP, Paneet B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:393–42.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.